Pfizer announced positive phase 2b results for PF’3944, showing that monthly dosing delivered up to 12.3% placebo-adjusted weight loss while maintaining safety in adults with obesity or overweight without diabetes.
Lupin partners with TB Alliance to fast-track the clinical development and commercialization of Telacebec for treating TB, leprosy, and other mycobacterial infections.
Eli Lilly and Repertoire Immune Medicines have joined forces in a $1.93B deal to develop next-gen autoimmune therapies, aiming to restore immune balance without broad suppression.
AstraZeneca announced a $15 billion investment in China through 2030 to expand R&D, manufacturing, and advanced therapies, strengthening China-UK healthcare collaboration and delivering next-generation treatments worldwide.
The new wave of Nipah virus in India has once again placed the pharma industry in the limelight and why their involvement is more important than ever. In West Bengal, authorities confirmed two Nipah cases since December 2025, with extensive...
Lupin Limited has earned the highest ‘A’ leadership rating from CDP for climate change and water security, reinforcing its position among global sustainability leaders in the pharmaceutical industry.
Bayer and Vanderbilt University Medical Center (VUMC) have entered a five-year collaboration to accelerate the development of new therapies for cardiovascular and kidney diseases, combining expertise in drug discovery and clinical research.
Eli Lilly has received FDA Breakthrough Therapy designation for sofetabart mipitecan, a novel antibody-drug conjugate showing early promise for patients with platinum-resistant ovarian cancer.
Sterling Hospitals, Ahmedabad, successfully performed a complex Robotic Whipple surgery, offering new hope in pancreatic cancer treatment with minimal invasiveness and faster recovery.
Novo Nordisk expands its diabetes cell therapy partnership with Aspect Biosystems, aiming to develop implantable insulin-producing cells and advance next-generation treatments for type 1 diabetes patients.